OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Optimizing Outcomes in Tenosynovial Giant Cell Tumors

home / peer-exchange / optimizing-outcomes-in-tenosynovial-giant-cell-tumors
Advertisement
Overview of Tenosynovial Giant Cell Tumors

EP. 1: Overview of Tenosynovial Giant Cell Tumors

May 8th 2020
Review of TSGCT Subtypes: Diffuse Vs Localized Disease

EP. 2: Review of TSGCT Subtypes: Diffuse Vs Localized Disease

May 8th 2020
Optimal Clinical Workup for Tenosynovial Giant Cell Tumors

EP. 3: Optimal Clinical Workup for Tenosynovial Giant Cell Tumors

May 8th 2020
TSGCT: Establishing a Differential Diagnosis

EP. 4: TSGCT: Establishing a Differential Diagnosis

May 8th 2020
TSGCT: Impacts of Delay in Diagnosis or Misdiagnosis

EP. 5: TSGCT: Impacts of Delay in Diagnosis or Misdiagnosis

May 8th 2020
What is the Role of Surgery in TSGCT?

EP. 6: What is the Role of Surgery in TSGCT?

May 8th 2020
Advertisement
TSGCT: Considering Scale of Surgery and Disease Factors

EP. 7: TSGCT: Considering Scale of Surgery and Disease Factors

May 8th 2020
Local Recurrence in Tenosynovial Giant Cell Tumors

EP. 8: Local Recurrence in Tenosynovial Giant Cell Tumors

May 8th 2020
Considerations for Radiation Therapy in TSGCT

EP. 9: Considerations for Radiation Therapy in TSGCT

May 8th 2020
Tenosynovial Giant Cell Tumors: Symptom and Pain Management

EP. 10: Tenosynovial Giant Cell Tumors: Symptom and Pain Management

May 8th 2020
Targeting CSF1 in Advanced TSGCT

EP. 11: Targeting CSF1 in Advanced TSGCT

May 8th 2020
CSF1 Inhibition in TSGCT: Managing Adverse Events

EP. 12: CSF1 Inhibition in TSGCT: Managing Adverse Events

May 8th 2020
Advertisement
Physicians’ Experiences With CSF1 Inhibition in TSGCT

EP. 13: Physicians’ Experiences With CSF1 Inhibition in TSGCT

May 8th 2020
TSGCT: Novel Agents and Future Directions in Care

EP. 14: TSGCT: Novel Agents and Future Directions in Care

May 8th 2020

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact